Part 4: First Results From VIKTORIA-1

We are pleased to present Part 4 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 4 of this series provides peer-to-peer physician perspectives on the first results from the VIKTORIA-1 trial.Topics include:Mechanisms of resistance to CDK4/6 inhibitorsRationale, design, and results of VIKTORIA-1 for the PIK3CA, wild-type cohortDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly